<DOC>
	<DOCNO>NCT02013154</DOCNO>
	<brief_summary>A study evaluate safety tolerability DKN-01 combination weekly paclitaxel participant refractory/recurrent esophageal , gastro-esophageal junction gastric cancer .</brief_summary>
	<brief_title>A Study DKN-01 Combination With Paclitaxel</brief_title>
	<detailed_description>Part A Dose-Escalation Study Participants Relapsed Refractory Esophageal Cancer Gastro-Esophageal Junction Tumors . Parts B , C , D E expansion cohort Patients Relapsed Refractory Esophageal Cancer , Gastro-Esophageal Junction Tumors Gastric Adenocarcinoma . Patients unable receive paclitaxel reason allow receive single agent DKN-01 part monotherapy substudy .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>In advanced esophagogastric malignancy : Participants histologically confirm recurrent metastatic esophageal gastroesophageal junction squamous cell adenocarcinoma Participants must refractory intolerant least one prior therapy ( y ) metastatic locally advanced disease Participants histologically confirm recurrent metastatic gastric adenocarcinoma document Wnt signal genetic alteration identify diagnostic test perform CLIA approve lab 1 . If prior therapy consist palliative chemoradiation therapy consider one line therapy 2 . Prior treatment paclitaxel part definitive therapy regimen acceptable . Patients unable receive paclitaxel reason allow receive DKN01 single agent . Tumor tissue mandatory pretreatment evaluation Must one tumor measurable radiographic image define Response Evaluation Criteria Solid Tumors ( RECIST ) . Patients evaluable measurable disease per RECIST criterion may enrol approval medical monitor . Must ambulatory Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . A performance status 2 ECOG scale may enter upon review approval medical monitor Have estimate life expectancy least 3 month , judgment investigator Diseasefree active second/secondary prior malignancy equal 2 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast Acceptable liver function : 1 . Bilirubin le equal ( ≤ ) 1.5 time upper limit normal ( ULN ) 2 . Aspartate aminotransferase ( AST ) ( SGOT ) , alanine aminotransferase ( ALT ) ( SGPT ) , gammaglutamyl transferase ( GGT ) alkaline phosphatase ≤ 2.5 time upper limit normal ( liver metastasis present , ≤ 5 x ULN allow ) Acceptable renal function : a. Creatinine normal age ; serum creatinine abnormal age patient must calculate creatinine clearance great equal ( ≥ ) 50 mL/min use Cockcroft Gault Method . Acceptable hematologic status : 1 . Granulocyte ≥ 1500 cells/mm3 2 . Hemoglobin ≥ 9 g/dL ( transfusion permit within 30 day study entry ) 3 . Platelet count ≥ 100,000 ( plt/mm3 ) Acceptable coagulation status : 1 . Prothrombin time/partial thromboplastin time ( PT/PTT ) ≤ 1.2 x ULN ( unless receive anticoagulation therapy , receive anticoagulation therapy , eligibility base upon international normalised ratio ( INR ) follow ) : 2 . INR ≤ 1.6 ( unless receive anticoagulation therapy ) . If receive anticoagulant : INR ≤ 3.0 active bleeding , ( i.e. , bleed within 14 day prior first dose study therapy ) For men woman childproducing potential , use effective contraceptive method study 6 month follow last dose study drug Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) study , must agree use adequate contraception prior study entry 6 month last dose study drug . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia Fridericiacorrected QT interval ( QTcF ) &gt; 470 msec ( female ) &gt; 450 ( male ) , history congenital long QT syndrome . Any ECG abnormality opinion investigator would preclude safe participation study ; patient pacemaker QTc reliable measure require evaluation cardiologist exclude coexist cardiac condition would prohibit safe participation study Active , uncontrolled bacterial , viral , fungal infection , within 7 day study entry require systemic therapy Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) unless HCV RNA undetected/negative . History major organ transplant ( example : heart , lung , liver kidney ) History autologous allogenic bone marrow transplant Serious nonmalignant disease could compromise protocol objective opinion investigator and/or sponsor Pregnant nursing woman History osteonecrosis hip evidence structural bone abnormality proximal femur MRI scan symptomatic clinically significant . Degenerative change hip joint exclusionary . Screening asymptomatic participant require . Symptomatic central nervous system ( CNS ) malignancy metastasis . Participants treat CNS metastasis eligible provided disease radiographically stable , asymptomatic , currently receive corticosteroid and/or anticonvulsant . Radiation must complete least 14 day prior study entry . Screening asymptomatic participant without history CNS metastases require Clinically significant peripheral neuropathy time study entry . Patients preexist peripheral neuropathy allow receive single agent DKN01 . Known osteoblastic bony metastasis . Screening asymptomatic participant without history metastatic bony lesion require Treatment surgery chemotherapy within 21 day prior study entry ( 42 day nitrosoureas mitomycin C ) Treatment low dose chemotherapy concurrent radiation within 14 day prior study entry Treatment radiation therapy within 14 day prior study entry Participants currently receive investigational agent receive investigational agent within 30 day prior study entry Previously treat antiDkk1 therapy Participants history hypersensitivity reaction TAXOL® drug formulate Cremophor® EL ( polyoxyethylated castor oil ) . Patients exhibit hypersensitivity eligible receive single agent DKN01 . Significant allergy pharmaceutical therapy , opinion investigator , pose increase risk participant</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>